Ionpath Announces Executive Chair Appointment and CEO Promotion
06 Dec 2023
Executive Change
MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a pioneer in high-plex spatial proteomics, today announced that Paul Davy, former Vice President of Customer Experience, has been appointed CEO of the company. Outgoing CEO David Summa is now Executive Chairman of Ionpath’s Board of Directors.
Mr. Summa served as CEO at Ionpath, leading the company’s transition from a traditional hardware business to a hardware-as-service business, concluding with the recent launch of the MIBIplus service at the annual meeting of the Society for Immunotherapy of Cancer. Currently, Mr. Summa is a Venture Partner with Genoa Ventures. He has 12 years of prior CEO experience at four startups, and was a partner at McKinsey & Company, where he led the Innovation practice.
“I enjoyed serving as CEO at Ionpath during this period of transition. Ionpath has an exceptional team, founders, and Board,” said Mr. Summa. “We were able to pivot and launch MIBIplus in less than six months. I look forward to continued involvement as Chairman and am pleased to pass the torch to Paul Davy.”
Mr. Davy brings more than 20 years of experience in the life sciences industry. He has led multinational teams at industry-leading life science companies including Molecular Devices and Pall Corporation. He joined Ionpath in 2021 and has been responsible for creating an exceptional customer experience across the company’s portfolio of products and services.
Mr. Davy commented: "As CEO of Ionpath and with our dedicated team, we will remain focused on driving innovation in spatial biology. Together, we aim to empower the scientific community to achieve groundbreaking advancements, particularly in fields like immuno-oncology and neuroscience, with our MIBI technology."
To view the management team updates at Ionpath, visit the management page.
About Ionpath
Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.